Literature DB >> 34196304

Influenza vaccination in the elderly boosts antibodies against conserved viral proteins and egg-produced glycans.

Jiwon Jung1, Sophia T Mundle2, Irina V Ustyugova2, Andrew P Horton3, Daniel R Boutz4, Svetlana Pougatcheva2, Ponraj Prabakaran2, Jonathan R McDaniel3, Gregory R King5, Daechan Park5, Maria D Person6, Congxi Ye4,7, Bing Tan3, Yuri Tanno3, Jin Eyun Kim1, Nicholas C Curtis7, Joshua DiNapoli2, Simon Delagrave2, Ted M Ross8, Gregory C Ippolito4,9, Harry Kleanthous2, Jiwon Lee7, George Georgiou1,3,4,5,9.   

Abstract

Seasonal influenza vaccination elicits a diminished adaptive immune response in the elderly, and the mechanisms of immunosenescence are not fully understood. Using Ig-Seq, we found a marked increase with age in the prevalence of cross-reactive (CR) serum antibodies that recognize both the H1N1 (vaccine-H1) and H3N2 (vaccine-H3) components of an egg-produced split influenza vaccine. CR antibodies accounted for 73% ± 18% of the serum vaccine responses in a cohort of elderly donors, 65% ± 15% in late middle-aged donors, and only 13% ± 5% in persons under 35 years of age. The antibody response to non-HA antigens was boosted by vaccination. Recombinant expression of 19 vaccine-H1+H3 CR serum monoclonal antibodies (s-mAbs) revealed that they predominantly bound to non-HA influenza proteins. A sizable fraction of vaccine-H1+H3 CR s-mAbs recognized with high affinity the sulfated glycans, in particular sulfated type 2 N-acetyllactosamine (Galβ1-4GalNAcβ), which is found on egg-produced proteins and thus unlikely to contribute to protection against influenza infection in humans. Antibodies against sulfated glycans in egg-produced vaccine had been identified in animals but were not previously characterized in humans. Collectively, our results provide a quantitative basis for how repeated exposure to split influenza vaccine correlates with unintended focusing of serum antibody responses to non-HA antigens that may result in suboptimal immunity against influenza.

Entities:  

Keywords:  Adaptive immunity; Infectious disease; Influenza; Vaccines

Mesh:

Substances:

Year:  2021        PMID: 34196304      PMCID: PMC8245176          DOI: 10.1172/JCI148763

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  82 in total

1.  Intrinsic defects in B cell response to seasonal influenza vaccination in elderly humans.

Authors:  Daniela Frasca; Alain Diaz; Maria Romero; Ana Marie Landin; Mitch Phillips; Suzanne C Lechner; John G Ryan; Bonnie B Blomberg
Journal:  Vaccine       Date:  2010-10-23       Impact factor: 3.641

2.  Preexisting immunity shapes distinct antibody landscapes after influenza virus infection and vaccination in humans.

Authors:  Haley L Dugan; Jenna J Guthmiller; Philip Arevalo; Min Huang; Yao-Qing Chen; Karlynn E Neu; Carole Henry; Nai-Ying Zheng; Linda Yu-Ling Lan; Micah E Tepora; Olivia Stovicek; Dalia Bitar; Anna-Karin E Palm; Christopher T Stamper; Siriruk Changrob; Henry A Utset; Lynda Coughlan; Florian Krammer; Sarah Cobey; Patrick C Wilson
Journal:  Sci Transl Med       Date:  2020-12-09       Impact factor: 17.956

3.  Persistent Antibody Clonotypes Dominate the Serum Response to Influenza over Multiple Years and Repeated Vaccinations.

Authors:  Jiwon Lee; Philipp Paparoditis; Andrew P Horton; Alexander Frühwirth; Jonathan R McDaniel; Jiwon Jung; Daniel R Boutz; Dania A Hussein; Yuri Tanno; Leontios Pappas; Gregory C Ippolito; Davide Corti; Antonio Lanzavecchia; George Georgiou
Journal:  Cell Host Microbe       Date:  2019-02-19       Impact factor: 21.023

4.  Host antigen as the sulphated moiety of influenza virus haemagglutinin.

Authors:  J C Downie
Journal:  J Gen Virol       Date:  1978-11       Impact factor: 3.891

5.  Antibodies to PB1-F2 protein are induced in response to influenza A virus infection.

Authors:  Ingrid Krejnusová; Hana Gocníková; Magdaléna Bystrická; Hana Blaskovicová; Katarína Poláková; Jonathan Yewdell; Jack Bennink; Gustáv Russ
Journal:  Arch Virol       Date:  2009-08-12       Impact factor: 2.574

6.  Plasmablast antibody repertoires in elderly influenza vaccine responders exhibit restricted diversity but increased breadth of binding across influenza strains.

Authors:  Chia-Hsin Ju; Lisa K Blum; Sarah Kongpachith; Nithya Lingampalli; Rong Mao; Petter Brodin; Cornelia L Dekker; Mark M Davis; William H Robinson
Journal:  Clin Immunol       Date:  2018-02-02       Impact factor: 3.969

7.  Antigenic Fingerprinting of Antibody Response in Humans following Exposure to Highly Pathogenic H7N7 Avian Influenza Virus: Evidence for Anti-PA-X Antibodies.

Authors:  Surender Khurana; Ka Yan Chung; Elizabeth M Coyle; Adam Meijer; Hana Golding
Journal:  J Virol       Date:  2016-09-29       Impact factor: 5.103

8.  Preliminary assessment of the efficacy of a T-cell-based influenza vaccine, MVA-NP+M1, in humans.

Authors:  Patrick J Lillie; Tamara K Berthoud; Timothy J Powell; Teresa Lambe; Caitlin Mullarkey; Alexandra J Spencer; Matthew Hamill; Yanchun Peng; Marie-Eve Blais; Christopher J A Duncan; Susanne H Sheehy; Tom Havelock; Saul N Faust; Rob Lambkin Williams; Anthony Gilbert; John Oxford; Tao Dong; Adrian V S Hill; Sarah C Gilbert
Journal:  Clin Infect Dis       Date:  2012-03-22       Impact factor: 9.079

9.  Interim Estimates of 2019-20 Seasonal Influenza Vaccine Effectiveness - United States, February 2020.

Authors:  Fatimah S Dawood; Jessie R Chung; Sara S Kim; Richard K Zimmerman; Mary Patricia Nowalk; Michael L Jackson; Lisa A Jackson; Arnold S Monto; Emily T Martin; Edward A Belongia; Huong Q McLean; Manjusha Gaglani; Kayan Dunnigan; Angie Foust; Wendy Sessions; Juliana DaSilva; Shoshona Le; Thomas Stark; Rebecca J Kondor; John R Barnes; David E Wentworth; Lynnette Brammer; Alicia M Fry; Manish M Patel; Brendan Flannery
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2020-02-21       Impact factor: 17.586

10.  IMGT/V-QUEST: the highly customized and integrated system for IG and TR standardized V-J and V-D-J sequence analysis.

Authors:  Xavier Brochet; Marie-Paule Lefranc; Véronique Giudicelli
Journal:  Nucleic Acids Res       Date:  2008-05-24       Impact factor: 16.971

View more
  5 in total

1.  Markers of systemic inflammation are positively associated with influenza vaccine antibody responses with a possible role for ILT2(+)CD57(+) NK-cells.

Authors:  Emilie Picard; Sarah Armstrong; Melissa K Andrew; Laura Haynes; Mark Loeb; Graham Pawelec; George A Kuchel; Janet E McElhaney; Chris P Verschoor
Journal:  Immun Ageing       Date:  2022-05-26       Impact factor: 9.701

Review 2.  An Immunoproteomic Survey of the Antibody Landscape: Insights and Opportunities Revealed by Serological Repertoire Profiling.

Authors:  Steven Ionov; Jiwon Lee
Journal:  Front Immunol       Date:  2022-02-01       Impact factor: 7.561

3.  Decreased vaccine protection of egg-based influenza vaccine in the elderly and nonhemagglutinin-focused immunity.

Authors:  Karen J Gonzalez; Eva M Strauch
Journal:  J Clin Invest       Date:  2021-08-02       Impact factor: 19.456

Review 4.  Safety, Immunogenicity, Efficacy and Effectiveness of Inactivated Influenza Vaccines in Healthy Pregnant Women and Children Under 5 Years: An Evidence-Based Clinical Review.

Authors:  Amit Bansal; Mai-Chi Trieu; Kristin G I Mohn; Rebecca Jane Cox
Journal:  Front Immunol       Date:  2021-10-06       Impact factor: 7.561

5.  Dynamics of infection-elicited SARS-CoV-2 antibodies in children over time.

Authors:  Lauren E Gentles; Leanne Kehoe; Katharine H D Crawford; Kirsten Lacombe; Jane Dickerson; Caitlin Wolf; Joanna Yuan; Susanna Schuler; John T Watson; Sankan Nyanseor; Melissa Briggs-Hagen; Sharon Saydah; Claire M Midgley; Kimberly Pringle; Helen Chu; Jesse D Bloom; Janet A Englund
Journal:  medRxiv       Date:  2022-01-25
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.